Navigation Links
Switching an antibiotic on and off with light
Date:3/21/2014

This news release is available in German.

Scientists of the KIT and the University of Kiev have produced an antibiotic, whose biological activity can be controlled with light. Thanks to the robust diarylethene photoswitch, the antimicrobial effect of the peptide mimetic can be applied in a spatially and temporally specific manner. This might open up new options for the treatment of local infections, as side effects are reduced. The researchers present their photoactivable antibiotic with the new photomodule in a "Very Important Paper" of the journal "Angewandte Chemie".

Photoswitchable molecules modify their structure and properties when exposed to light of an adequate wavelength. Among the photoswitches known are diarylethenes. By reversible photoisomerization, i.e. a reversible light-induced internal relocation of the molecule, the open form is turned into a closed form. Such photoswitch-able molecules are applied in molecular electronics and many other areas. Particularly interesting opportunities result from the insertion of photoswitches into biomolecules to control their activity by light. Interest focuses on so-called peptide mimetics, compounds whose major structural elements emulate a peptide, i.e. a small protein.

For the first time now, a group of researchers headed by Professor Anne S. Ulrich, Director of the Institute for Biological Interfaces 2 (IBG2) and holder of the Chair for Biochemistry at the Institute of Organic Chemistry (IOC) of KIT, has produced a photoswitchable peptide mimetic based on a diarylethene scaffold that can be photoisomerized reversibly. The scientists modified this building block into an amino acid analog and incorporated it directly into the backbone of the annular peptide antibiotic Gramicidin S. Biological activity of the resulting peptide mimetic can be controlled spatially and temporally with the help of UV and visible light. To demonstrate this, the scientists treated a bacterial film with the inactivated antibiotic and exposed it to light via a mask. As a result, the photoswitchable diarylethene was converted from a closed into an open form. Due to the structural modification induced, the entire substance molecule had a much higher antimicrobial effect. "In the future, such photoactivable antibiotics might be used as smart therapeutic agents against local bacterial infections," Professor Anne S. Ulrich explains. "Usual side effects can also be minimized by switching." Based on this strategy, new peptide-based agents against cancer might be feasible, as the newly developed photoactivable building block can also be applied in other peptide sequences.

The editors of the journal "Angewandte Chemie", in which the researchers of KIT and the University of Kiev present their photo-activable antibiotic and their photoswitch, have rated this publication a "VIP Very Important Paper".


'/>"/>

Contact: Monika Landgraf
presse@kit.edu
49-721-608-47414
Karlsruher Institut fr Technologie (KIT)
Source:Eurekalert  

Related biology news :

1. How phenotype switching can make melanoma become metastatic and resistant to drugs
2. Comeback of an abandoned antibiotic
3. Fighting antibiotic resistance with molecular drill bits
4. A tricky balancing act: Antibiotics versus the gut microbiota
5. Spread of antibiotic resistance understood by unravelling bacterial secretion system
6. UT Arlington undergrad honored for research on antibiotic resistant infection
7. Notre Dame chemists discover new class of antibiotics
8. Fossilized human feces from 14th century contain antibiotic resistance genes
9. €85 million for new way to carry out antibiotic drug discovery
10. Promising class of antibiotics discovered for treatment of drug-resistant tuberculosis
11. Drug alternatives to antibiotics may not be perfect, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Switching an antibiotic on and off with light
(Date:10/4/2017)...  GCE Solutions, a global clinical research organization (CRO), announces the ... on October 4, 2017. Shadow is designed to assist medical writers ... 0070 of the European Medicines Agency (EMA) in meeting the requirements ... ... ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology: